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In metastatic colorectal cancer (mCRC), an improved understanding of the underlying pathology and
molecular biology has successfully merged with advances in diagnostic techniques and local/systemic
therapies as well as improvements in the functioning of multidisciplinary teams, to enable tailored
treatment regimens and optimized outcomes. Indeed, as a result of these advancements, median survival
for patients with mCRC is now in the range of 20–24 months, having approximately tripled in the last
20 years. The identiﬁcation of KRAS as a negative predictive marker for activity of epidermal growth
factor receptor (EGFR)-targeted monoclonal antibodies (mAbs), such as panitumumab (Amgen, Thousand
Oaks, USA) and cetuximab (ImClone, Branchburg, USA), has perhaps had the greatest impact on patient
management. This meant that, for the ﬁrst time, mCRC patients unlikely to respond to a targeted therapy
could be deﬁned ahead of treatment. Ongoing controversies such as whether patients with KRAS G13D-
(or BRAF V600-) mutated tumours can still respond to EGFR-targeted mAbs and the potential impact of
inter- and intra-tumour heterogeneity on tumour sampling show that the usefulness of KRAS as a
biomarker has not yet been exhausted, and that other downstream biomarkers should be considered.
Conversely, a predictive biomarker for anti-angiogenic agents such as bevacizumab (Genentech, San
Francisco, USA) in the mCRC setting is still lacking. In this review we will discuss the discovery and
ongoing investigation into predictive biomarkers for mCRC as well as how recent advances have impacted
on clinical practice and ultimately the overall cost of treatment for these patients.
 2013 Elsevier Ltd.Open access under CC BY-NC-ND license.Introduction
Until relatively recently we believed that cancer could
essentially be treated using the same combinations and sequences
of locoregional (surgery and/or radiotherapy) and systemic
(chemotherapy) treatments in all patients. However, we arenow in a transitional period where we are embracing a more
personalised approach to cancer management. The heterogeneous
nature of cancer means that personalised medicine (i.e. tailoring
therapy to an individual patient) is a promising approach for
maximising efﬁcacy and minimising the toxicity of treatment. It
also facilitates efﬁcient healthcare delivery and generates cost
savings because treatment is only given to those likely to beneﬁt
and so costs associated with drug wastage, hospital resource
utilisation and side-effect management are reduced. To successfully
deliver personalised medicine, it is necessary to have a clear
understanding of the pathology and molecular underpinnings of a
disease, as well as the associated clinical characteristics that deﬁne
different patient sub-populations with different outcomes in relation
to a given treatment. Identifying the optimum treatment strategy
also involves an understanding of a patient’s medical history,
disease status, and sometimes, their socio-economic situation, and
consideration of the wider healthcare framework, such as the
availability of hospital resources and reimbursement.
The ultimate goal of personalised medicine is to deﬁne a disease
sufﬁciently to enable identiﬁcation and treatment of only those
Fig. 1. Median overall survival for patients with metastatic colorectal cancer
treated at the M.D. Anderson Cancer Center and the Mayo Clinic by year of diagnosis
(error bars are 95% conﬁdence intervals).12 Reprinted with permission  2009
American Society of Clinical Oncology: Kopetz S, et al. J Clin Oncol 2009;
27(22):3677–3683. All rights reserved.
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almost exclusively discussed in the context of targeted therapies,
chemotherapy also has the potential to be tailored to individual
patients. Advances in genomic and proteomic technologies and
the implementation of major collaborative studies such as the
human genome project and genome-wide association studies
(GWAS), have already generated much data and are leading to
the identiﬁcation of many biomarkers – a characteristic that
can be objectively measured and evaluated as an indicator of
pathogenic processes or treatment responses. Biomarkers have
been identiﬁed for: early detection/risk stratiﬁcation (diagnostic
markers); the likely course of a given disease (prognostic markers);
and prediction of treatment safety/efﬁcacy outcome (predictive
markers).
The principle of targeted therapy was ﬁrst proposed by Paul
Ehrlich more than 100 years ago, when he coined the term ‘magic
bullet’.1 Immunohistochemistry (IHC) provided one of the ﬁrst
opportunities to personalise medicine and was effectively used in
breast cancer to identify patients with tumours expressing
oestrogen and/or progesterone receptors, who were candidates
for ‘targeted’ hormonal therapies like tamoxifen (AstraZeneca,
Delaware, USA). Furthermore, since its discovery more than
30 years ago,2hybridoma technology has enabled production of
large amounts of monoclonal antibodies (mAbs) targeted to
speciﬁc tumour antigens, and has led to a vast array of new
diagnostic and therapeutic options. These advances are already
revolutionising cancer screening, drug development and treatment
selection, and are major factors in personalising medicine in the
21st century. This concept has gained momentum in recent years
with the development of other successful therapies such as
imatinib mesylate (Novartis, New Jersey, USA)3 for chronic myeloid
leukaemia (CML) and gastrointestinal stromal tumours (GIST) and
trastuzumab (Genentech, San Francisco, USA)4 for breast and
gastric cancers. These agents target speciﬁc molecular alterations
(abnormal protein tyrosine kinase activity for imatinib,
overexpression of human epidermal growth factor receptor-2
[HER-2] for trastuzumab), which are now used as predictive
biomarkers of response, thereby allowing these drugs to be
targeted to individuals with the appropriate tumour characteristics.
Colorectal cancer (CRC) is perhaps one of the best examples of
how an increased understanding of disease molecular biology
has successfully merged with improved diagnostic techniques,
advances in local/systemic therapy, and improvements in the
functioning of multidisciplinary teams, to enable tailored
treatment regimens and optimized outcomes.Evolution of personalised therapy in metastatic CRC (mCRC)
Globally, CRC is the third most commonly diagnosed cancer in
males and the second in females5 and is the second leading cause
of cancer mortality in the United States, accounting for 9% of all
cancer deaths.6 Approximately one-quarter of CRC patients have
metastases at diagnosis and a further 33–50% develop metastases
over their disease course.5,7 Surgical resection offers the possibility
of cure for a small minority of patients with mCRC and isolated
metastases.8 Management by a multidisciplinary team including,
for example, surgeons, oncologists, interventional radiologists,
radiotherapists, and nurses, increases the number of patients able
to undergo potentially curative treatment and has consequently
improved patient survival.7,9 Together, advances in local and
systemic therapy have led to improvements in survival10 withmedian
survival in mCRC increasing from approximately 8–24 months9,11,
over the last 20 years. The improvements in survival times in
mCRC patients diagnosed between 1990 and 2006 at two large
specialised institutes are exempliﬁed in Fig. 1.12 The availabilityof new cytotoxic and targeted therapies and the implementation
of personalised medicine have been instrumental in this process.13Evolution of systemic therapy for mCRC
Chemotherapy has been standard care for mCRC patients for
many years, and is based mainly on the use of three agents:
5-ﬂuorouracil (5-FU; APP Pharmaceuticals, Schaumburg, USA),
irinotecan (Pﬁzer, New York, USA)14,15 and oxaliplatin
(Sanoﬁ-Aventis, Bridgewater, USA).16,17 Infusional 5-FU regimens-
such as FOLFIRI18 or FOLFOX19 have better efﬁcacy than earlier
bolus 5-FU regimens and currently provide the backbone of
therapy.20 Capecitabine (Genentech, San Francisco, USA),21 an oral
formulation of 5-FU, is also available.
Whilst the vast majority of biomarker research has focussed on
targeted therapies, efforts are continuing to identify predictive
markers of response or resistance to chemotherapy. Up to now,
however, there are only a few noteworthy examples. Although
results are somewhat conﬂicting, high thymidylate synthase (TS)
expression has generally been linked with poorer outcomes during
5-FU-based therapy,22,23 and 5-FU adjuvant treatment may also be
ineffective in tumours with microsatellite instability.13 Irinotecan
was one of the ﬁrst chemotherapy agents to be dosed based on
the recipient’s pharmacogenomics; reduced irinotecan doses
should be considered in patients homozygous for the ⁄28 variant
form of UGT1A1 as they are unable to clear irinotecan as quickly
as normal and, therefore, suffer more severe haematological side
effects.24 Furthermore, homozygosity for the ⁄28 variant form of
UGT1A1 has been linked with improved efﬁcacy of FOLFIRI.25
The most promising predictive marker of resistance to oxalipla-
tin is excision repair cross-complementing C1 (ERCC1) expres-
sion,26 and although there is currently no standard test available,
it is possible that ERCC1 testing may become routine in mCRC
patients in the future. Genetic differences in the glutathione
transferase pathway have also been suggested to lead to higher
rates of neurotoxicity during oxaliplatin therapy,27 however, this is
yet to be conﬁrmed and has not yet impacted on clinical practice.
In addition, a FOLFOX response predictor has recently been
constructed based on gene expression proﬁles of responding and
non-responding patients.28 Initial results suggest that the overall
accuracy of this predictor is high (92.5%) and therefore it may offer
the possibility of selecting patients who would beneﬁt from FOLFOX.
Fig. 2. An overview of the epidermal growth factor receptor (EGFR) pathway and its
main downstream effectors (top). Expected outcomes of anti-EGFR monoclonal
antibody (mAb) therapy (bottom): sensitivity (tumour response) when EGFR is
activated (increased copy number, ligand overexpression, other unknown
mechanisms) and downstream effectors are wild type (left); Resistance (tumour
growth and metastasis) when downstream effectors such as KRAS, BRAF or PI3K are
activated or PTEN is inactivated (right).106 Reprinted by permission from Macmillan
Publishers Ltd on behalf of Cancer Research UK: Di Fiore F, et al. Br J Cancer 2010;
103(12):1765–1772.
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Targeting angiogenesis – bevacizumab
The ﬁrst biological targeted therapy to be used in mCRC was the
vascular endothelial growth factor-A (VEGF-A)-targeted agent,
bevacizumab (Genentech, San Francisco, USA). When used in com-
bination, bevacizumab improves progression-free survival (PFS)
compared with chemotherapy alone, while the effects on objective
response rate (ORR) and overall survival (OS) are less consistent
in the 1st-29–31 and 2nd-line32 mCRC settings. Generally the
overall magnitude of beneﬁt appears to vary depending on the
choice of chemotherapy backbone, and is seemingly greater with
irinotecan-based regimens.33,34
As more effective therapies became available, the need for
predictive biomarkers to enable optimum treatment selection for
each patient increased. Such markers are particularly important
in mCRC because of the heterogeneity of response among colon
tumours and the toxicities and costs associated with the available
therapies.13 Despite much research35–40 and the broad application
of bevacizumab in many patients, it is still poorly understood
which patients/tumour characteristics are best treated with
anti-angiogenics, and no validated predictive markers of
response/resistance are currently available.41 Recently, VEGF-A,
TS, and tissue inhibitor of metalloproteinase 3 were identiﬁed as
factors that were differentially expressed in responding or
non-responding patients.39 A model utilising these three genes
appeared to accurately predict response to bevacizumab39 but
needs further evaluation in larger numbers of patients. In addition,
recent data from the AGITG MAX trial suggest that high
VEGF-Dexpression could be predictive of resistance to
bevacizumab.40 Results of a second study suggested that high
levels of an anti-angiogenic splice variant of VEGF-A (VEGF165b)
could have similar effects.42 Further investigation of the impact
of these potential markers of bevacizumab activity is warranted.
Some tumours show intrinsic resistance to bevacizumab and,
when they do occur, responses are often transitory with patients
showing restoration of tumour growth due to evasive resistance.43
Furthermore, in some preclinical studies, anti-angiogenic treatment
has been shown to elicit malignant progression of tumors and to
increase local invasion and distant metastasis.44 Various mechanisms
appear to be involved in different tumour contexts43 such as
upregulation of alternative proangiogenic signalling,45 recruitment
of vascular progenitor cells and pro-angiogenic monocytes46 and
increased tight pericyte coverage in the tumour vasculature.47
However, these have not yet been shown to occur in patients with
mCRC undergoing anti-angiogenic treatment. Nonetheless, these
preclinical observations should motivate additional studies and
should they be validated, could lead to combinatorial treatment
strategies integrating anti-angiogenics with drugs targeting the
appropriate resistance mechanisms. Based on results of a recent
preclinical study,44 it is of interest to clinically evaluate strategies
combining anti-invasive and anti-metastatic drugs with anti-angiogenics,
with the aim of producing a more enduring efﬁcacy.
Targeting epidermal growth factor signalling – panitumumab and
cetuximab
Advances in the understanding of mCRC have also led to the
development of mAbs targeting the epidermal growth factor receptor
(EGFR), such as panitumumab (Amgen, Thousand Oaks, USA)
or cetuximab (ImClone, Branchburg, USA). Initial monotherapy
studies included patients whose tumours expressed EGFR, but
produced low ORRs,48 suggesting that other factors were important
for response to these agents.49 Nonetheless, combining chemother-
apy with EGFR-targeted mAbs improved efﬁcacy in the 1st-50–52
and 2nd-line53,54 mCRC settings. Such regimens were generally
associated with higher ORRs compared with the equivalentbevacizumab-containing regimens,55 which may impact on treat-
ment choice in patients with resectable/potentially resectable dis-
ease. Furthermore, unlike bevacizumab, EGFR-targeted mAbs are
active as monotherapy in later lines of treatment.48,56 Choice of
chemotherapy backbone may also impact on the effectiveness of
EGFR-targeted mAbs, although such observations have only been
noted with cetuximab to date. The COIN57 and NORDIC VII58 trials
reported no efﬁcacy beneﬁts on adding cetuximab to oxaliplatin-
based regimens (capecitabine/oxaliplatin and 5-FU/oxaliplatin/
folinic acid, respectively), raising concern about using these agents
in combination. The use of oral/bolus ﬂuoropyrimidines in both
studies (rather than an infusional regimen) may explain these re-
sults. This hypothesis is substantiated by the FUTURE study, which
reported inferior results (not statistically signiﬁcant) for cetux-
imab/UFT (oral) vs. cetuximab/FOLFOX4 (infusional).59 In line with
this, efﬁcacy beneﬁts were noted on addition of EGFR-targeted
mAbs to FOLFOX4 in the PRIME52 and OPUS60 trials. Interestingly,
in the AIO 010461 and CELIM62 trials, which used oral and infusion-
alﬂuoropyrimidines, respectively, cetuximab had similar activity
when combined with oxaliplatin- or irinotecan-based regimens.
The KRAS gene: a game changer for mCRC
Biomarker development for EGFR-targeted mAbs has focussed
on the impact of alterations in EGFR and its downstream effectors
(Fig. 2). The most important development in mCRC management in
recent years was the discovery that mutated tumour KRAS status
predicted for lack of response to EGFR-targeted mAbs.
Approximately 27-43% of tumours in mCRC patients harbour KRAS
gene mutations, leading to constitutive activation of downstream
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discovery meant that for the ﬁrst time in mCRC, patients unlikely
to beneﬁt from a targeted therapy could be identiﬁed ahead of
treatment. Indeed, tumour KRAS testing is now mandatory in
potential candidates for EGFR-targeted mAb therapy. The presence
of KRAS mutations in CRC tumours may also be an adverse
prognostic indicator,64 particularly if the glycine to valine
alteration at codon 12 (G12V) is present.65 Furthermore, there is
a negative interaction in patients with KRAS-mutant tumours
receiving an EGFR-targeted mAb combined with oxaliplatin-based
therapy; these patients have worse efﬁcacy outcomes than
similar patients receiving oxaliplatin-based therapy alone.52,57
Interestingly, however, when treated with oxaliplatin-based
regimens such as FOLFOX6 alone, recent retrospective data suggest
that patients with KRAS-mutant disease respond better than
patients with KRAS-wild-type mCRC.66Cost implications of KRAS testing
Although the implementation of KRAS testing is associated with
additional upfront costs, as might be expected, overall, it is associ-
ated with cost savings.67–71 For example, under most scenarios
tested, using KRAS testing to select mCRC patients for EGFR-
targeted mAb therapy saved $7500-$12,400 per patient in the
United States and €3900–9600 per patient in Germany (Table 1).69
Based on cost savings for monotherapy of $7456-$8040, using KRAS
testing should save $377–402 million in the United States each
year. In another European cost-effectiveness analysis, using KRAS
testing to limit treatment to patients with KRAS-wild-type tumours
led to savings of €779.42 per patient per cycle.71 Whereas, in Japan,
implementation of KRAS testing before deciding whether to use
EGFR-targeted mAbs was reported to save £32 million per year.70The G13D controversy
Within the KRAS gene, most mutations occur in codons 12 and
13 and seven common mutations in these regions account for
98% of all observed KRAS mutations in CRC.72 The original
analyses of response by tumour KRAS status during EGFR-targeted
mAb therapy grouped KRAS codon 12 and 13 mutations together,
and did not look at the impact of individual mutations. Recently,
however, reports have suggested that different KRAS mutations
may have different biological characteristics with respect toTable 1
Cost and effectiveness data associated with KRAS testing in the United States and German
Cancer 2012; 131(2):438-445,copyright 2012
Strategy Cost/pt
(US)
Cost
saving/
pt (US)
Cost/pt
(Germany)
C
sa
(G
Panitumumab monotherapy with KRAS testing $19,656 $7546 €13,787 €4
Panitumumab monotherapy without KRAS
testing
$27,202 – €18,399 –
Cetuximab monotherapy with KRAS testing $22,893 $8040 €13,588 €3
Cetuximab monotherapy without KRAS testing $30,933 – €17,444 –
Combination therapya with KRAS testing
(combination therapy for KRAS WT & no
chemotherapy for KRAS MT)
$35,075 $13,501 €26,292 €9
Combination therapya with KRAS testing
(combination therapya for KRAS WT &
irinotecan/FOLFIRI only for KRAS MT)
$36,148 $12,428 – –
Combination therapya without KRAS testing $48,576 – €35,852 –
ICER, incremental cost-effectiveness ratio; LYS, life-year saved; MT, mutant; pt, patient;
a Combination therapy is cetuximab + irinotecan in the United States and cetuximab +
leucovorin.treatment sensitivity. Tumours harbouring mutations of the glycine
to aspartate at KRAS codon 13 (G13D) have been suggested to
retain cetuximab sensitivity and several small retrospective studies
reported improved outcomes in some patients harbouring these
mutations during cetuximab therapy.73–77 In contrast, in a pooled,
post-hoc analysis of data from patients receiving panitumumab
treatment in three phase III trials, no single KRAS mutation
consistently predicted PFS or OS outcome.78 Indeed, in one of these
studies, the G12Vmutation was favourably associated with OS (but
not PFS) while G13D was unfavourably associated with both OS
and PFS in the panitumumab arm. Nonetheless, a trend towards
beneﬁt was observed on adding panitumumab to FOLFIRI in
patients with G13D-mutated tumours, which taken together with
data for cetuximab73 suggests a potential beneﬁt when EGFR-targeted
mAbs are used alongside irinotecan-based therapy in such
patients. However, until any association between speciﬁc KRAS
mutations and response are conﬁrmed in prospective studies
including predeﬁned patient populations (e.g. the AGITG ICE
CREAM trial79), it seems prudent to limit use of EGFR-targeted
mAbs to the licensed population (i.e. those with KRAS-wild-type
tumours). Interestingly, a recent retrospective study suggested that
KRAS codon 12 and 13-mutated mCRC may also have differential
impact on prognosis, with codon 13-mutated mCRC presenting as
a more aggressive disease frequently associated with local and
distant metastases at diagnosis.80
Ultimately, these data highlight the need to correctly validate a
biomarker in homogenous and, therefore, more clinically
meaningful populations before it is put into clinical practice.
However, the process of validating such markers can be complex,
especially for uncommon mutations where it can be difﬁcult to
get sufﬁcient patient numbers for an accurate picture to emerge
of their impact. There is also a need for consistent testing across
centres and for quality assurance measures to be in place to ensure
any potential associations between mutation status and outcome
are robust. The need for external quality assurance for KRAS testing
has recently been demonstrated;81 only 70% of laboratories
included in a recent study correctly identiﬁed the KRAS mutational
status of all test samples.81 Notably, of the mutations found, 30%
were false positives and false negatives, both of which would
likely negatively impact patient care through their inﬂuence on
treatment choice.y.69 Reprinted with permission of John Wiley and Sons: Vijayaraghavan A, et al. Int J
ost
ving/pt
ermany)
Effectiveness
(weeks)
ICER ($ or € per LYS)
612 18.26 –
18.26 Higher cost, same effectiveness compared with KRAS
testing
856 19.78 –
19.78 Higher cost, same effectiveness compared with KRAS
testing
560 24.26 Less expensive, less effective than combination
therapy without KRAS testing
25.83 $35,539 per LYS compared with combination
therapy with KRAS testing assuming KRAS MT
patients will not receive chemotherapy
25.83 Higher cost and same effectiveness compared with
previous KRAS testing strategy
US, United States; WT, wild-type.
FOLFIRI in Germany. The FOLFIRI regimen consists of irinotecan, 5-ﬂuorouoracil and
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Although mutant KRAS is undoubtedly an excellent predictor
for lack of activity of EGFR-targeted mAbs, with its implementa-
tion response rates only rose from 15% in an unselected popula-
tion to 30% in those with KRAS-wild-type tumours,13 therefore, a
prognostic impact of mutant KRAS is likely and additional factors
inﬂuencing the course of disease must be important.82,83 The
ongoing need to identify and validate other biomarkers of
response and resistance has led to much research in this area,
with the aim of further improving our ability to specify likely
responders and subsequently improve treatment outcomes and
decrease costs.
Potential new predictive biomarkers for EGFR-targeted mAbs
Tumour KRAS testing for codon 12/13 mutations is now a
prerequisite ahead of undergoing EGFR-targeted mAb treat-
ment,84–86 but should we consider testing the status of a panel of
other biomarkers in mCRC patients at this point in time? Although
there has been much research into other potential biomarkers,
many results have been inconsistent and there is also a lack of
validated tests, and so at present most are not routinely used in
clinical practice. For example, there is some evidence suggesting
that mutations at KRAS codons 61 and 146 (present in 2% of
colorectal tumours) have similar impact to mutations in codons
12 and 1387 as do mutations in NRAS.88 However, additional
research in larger groups of patients is needed if we are to
incorporate these mutations into routine clinical practice.
Emerging biomarkers for activity of EGFR-targeted mAbs and
their stage of development are brieﬂy reviewed below and the
relationships between such biomarkers and treatment response
are summarised in Fig. 3.
BRAF V600E mutations
After KRASmutations, BRAF V600E mutations currently have the
strongest evidence to support their use as a predictive biomarker
for EGFR-targeted mAb activity. Overall, BRAF V600E activating
mutations occur in approximately 10–15% of CRC tumours and
are generally mutually exclusive to KRAS mutations.13 Most but
not all of the available evidence links BRAF V600E mutations with
resistance to EGFR-targeted mAb therapy,89–94however, the impactFig. 3. Relationship between biomarkers and response to epidermal growth factor
receptor (EGFR) inhibitors in chemorefractory colorectal cancer. Approximately 70%
of responders may have an increased EGFR copy number. WT, wild-type; MT,
mutant.83 Reprinted with permission 2010 American Society of Oncology:
Hawkes E, et al. J Clin Oncol 2010; 28(28):e529-e531. All rights reserved.of tumour BRAF status on efﬁcacy of these treatments has not yet
deﬁnitively been addressed due to the relatively small number of
patients with BRAF mutations. Indeed, a retrospective analysis of
data from the CRYSTAL trial showed numeric improvements in
median PFS and OS (not statistically signiﬁcant) on addition of
cetuximab to FOLFIRI in patients with KRAS-wild-type/BRAF-
mutant disease.51 Mutated BRAF was also shown to be a negative
prognostic marker for outcome irrespective of treatment received
and the authors speculated that this strong prognostic effect could
explain in part why previous single-arm analyses were interpreted
as indicating that EGFR-targeted mAbs were ineffective in patients
with BRAF-mutant mCRC. BRAF inhibitors also show limited
single-agent activity in tumours bearing these mutations.95 A
recent study suggested that resistance to BRAF inhibition in BRAF
V600E-mutant CRC may be caused by feedback activation of
EGFR,93 therefore, it could be of interest to evaluate treatment
strategies targeting both BRAF and EGFR inhibition in a controlled
clinical trial in patients with tumours of this genotype.
In addition to worse prognosis, mutated BRAF is associated with
a characteristic pattern of gene expression.96,97 Furthermore, in
one study, some BRAF-wild-type/KRAS-mutated tumours and
double wild-type tumours showed a BRAF-mutated-like gene
expression proﬁle and similarly poor prognosis,97 suggesting a
common biology that would not be detected by BRAF testing alone.
Interestingly, the prevalence of BRAF V600E mutations appears
considerably higher in older females with KRAS-wild-type
right-sided colon cancers (50%) compared to unselected patients
(10%).96 This suggests that certain clinicopathological and molecu-
lar features may be useful to identify mCRC patients with a higher
prevalence of BRAF V600E mutation or worse prognosis. A
validated test has recently been launched for the BRAF V600E
mutation,98 but validated tests for other BRAF mutations are as
yet unavailable. Testing BRAFV600E status in patients with KRAS-
wild-type disease is associated with additional upfront costs.
Nonetheless, a recent European study using this approach to deﬁne
which patients should receive cetuximab treatment found it
to be the most cost-effective strategy compared with various
alternative scenarios including where only tumour KRAS status
was determined.99 BRAF V600E testing is now starting to be used
in clinical practice, but isn’t yet considered a fully validated marker
for EGFR-targeted mAb activity and isn’t routinely used in
treatment decision-making in most centres.Alterations to PI3K signalling
Changes in PI3K signalling, such as PIK3CA mutations94,100,101
and loss of PTEN expression/activity94,101–103 have generally been
linked with lack of response to EGFR-targeted mAbs, although
these data have been somewhat inconsistent and come from
relatively small studies. The PI3K pathway is in part modulated
by KRAS activation during EGFR signalling and so it is plausible that
alterations could predict for activity of EGFR-targeted mAbs.
Furthermore, data suggests that combining KRAS and BRAF muta-
tional analysis with evaluation of PIK3CA mutations and PTEN
expression status may permit identiﬁcation 70% of patients unli-
kely to respond to EGFR-targeted mAbs.104 However, there are no
standardized approaches for assessing these changes, particularly
for PTEN, with mutational status, IHC and gene copy number all
being used, making consolidation of the available data difﬁcult.
This emphasizes the importance of standardization of approach
and the need for validated tests if PIK3CA and PTEN status are to
become routinely used in clinical practice.Overexpression/ampliﬁcation of EGFR and its ligands
EGFR overexpression/ampliﬁcation has potential as a prognostic
marker in KRAS-wild-type patients105 but investigations into its
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results,105–108 likely due in part to differences in assay
methodology. Therefore, EGFR overexpression/ampliﬁcation is
not currently used as a predictive marker for EGFR-targeted mAbs.
Initial studies have indicated that overexpression of EGFR ligands
such as amphiregulin and epiregulin may, however, predict response
to cetuximab.109–111 For example, in one study, amphiregulin and
epiregulin expression were each signiﬁcantly associated with
ORR, PFS and OS outcomes in patients with KRAS-wild-type
tumours undergoing cetuximab plus irinotecan treatment.109
However, further studies are required to determine if these
molecules could become useful biomarkers in clinical practice
and to determine if reproducible assays can be deﬁned.
Mutation testing – is one tumour sample sufﬁcient?
It is debatable whether evaluating biomarker status of a single
biopsy from a single tumour is sufﬁcient to direct choice of tar-
geted therapy in mCRC because deregulation of EGFR signalling
can differ between primary and metastatic sites,112 potentially
impacting response to EGFR-targeted mAbs. For example, a recent
study suggested that while KRAS, BRAF and PIK3CA status could be
considered adequate markers in metastatic disease (concordant in
91%, 100% and 94% of cases, respectively), a much higher degree of
discordance was found between tumour sites in expression of
EGFR (concordant in 61%), PTEN (66%) and pAKT (54%).113
Mutation analysis of a single tumour biopsy sample may also
underestimate the mutational burden of heterogeneous
tumours,114,115 making it difﬁcult to accurately determine likely
resistance and also to validate new biomarkers of response. Phylo-
genetic reconstruction of tumour clonal architecture reveals
branched evolutionary growth, but reassuringly, common muta-
tions at the trunk of the phylogenetic tree are consistently
expressed and so may provide robust markers and therapeutic
targets.115 Intratumoural heterogeneity of KRAS and BRAF status
has been reported in multiple blocks taken from the same primary
tumour. In one study, the authors suggested that testing DNA from
only a single tumour block could lead to tumour KRAS status being
wrongly assigned in 10% of patients.114 However, preparing a
‘DNA cocktail’ from two or more blocks could improve detection
at minimal additional cost.
Mutation status may also change over the course of therapy as
resistance develops, begging the question whether serial mutation
testing could be useful. While repeated tumour biopsies at disease
progression may be a valuable approach to understand emerging
resistance, this strategy certainly imposes a burden on patients.
From an ethical standpoint, serial biopsies might ﬁnd acceptance
if it is clear that these could beneﬁt the patient by guiding an
effective course of action to overcome resistance. Two recent re-
ports have suggested that the emergence of KRAS mutations or
KRAS ampliﬁcation during cetuximab or panitumumab treatment
may be frequent drivers of resistance.116,117Interestingly, these
mutations could be detected non-invasively in patient sera after
5–6 months of treatment, months before radiological progression.
Mathematical modelling suggested that resistant clones bearing
these mutations were highly likely to be present at very low levels
in the patient’s tumours before treatment commenced, and that
these expanded rapidly following initiation of treatment.116
Importantly, the KRAS-mutant tumours were found to be sensitive
to combined EGFR-targeted mAb/MEK inhibitor treatment.117
Monitoring for KRAS mutations in sera during EGFR-targeted ther-
apy could, therefore, permit early initiation of combination treat-
ment that could prevent or delay progression, without the need
for more invasive tumour sampling. In addition, the emergence
of EGFR mutations have been linked to the development of cetux-
imab resistance during treatment,118 which if detected, couldtrigger a change of therapy to a more effective agent. Interestingly,
tumours with acquired EGFR ectodomain mutations (S492R) that
prevent cetuximab binding and, therefore, produce cetuximab
resistance can retain sensitivity to panitumumab,118,119 suggesting
that each of these agents may interact with the EGFR slightly
differently.
How can we sustain the progress?
The importance of sustaining development of speciﬁc targeted
therapies and their associated predictive biomarkers was
highlighted in a recent pooled analysis.120 Here, hazard ratios for
PFS and OS from published randomised controlled trials were
pooled and compared for three groups of agents: those directed
against a speciﬁc molecular target for which the target population
was selected by biomarker (e.g. panitumumab/cetuximab in
patients without KRAS mutations); less speciﬁc biologic targeted
agents (e.g. bevacizumab); and chemotherapeutic agents.120 The
clinical beneﬁt from targeted therapies was greater than for
chemotherapies, with the highest relative beneﬁt observed when
the target population was selected by biomarker. It is, therefore,
vital that we continue to identify druggable proteins driving cancer
progression alongside suitable biomarkers that enable accurate
selection of patients if more effective anticancer therapies are to
be developed. In the ﬁrst instance we must ensure that future
clinical trials are designed according to established and validated
biomarkers (e.g. KRAS) and then optimised biobanks from these
studies can be used to explore the impact of potential next-generation
biomarkers (e.g. alterations in PI3K signalling and expression levels of
EGFR ligands, etc.).
Supporting basic and translational research is key to furthering
the ‘omics’ revolution and will ensure the continuing identiﬁcation
of new drug targets and biomarkers. The integration of optimum
technologies such as high-throughput, next-generation sequencing
and protein and DNA microarrays is already revolutionising
biomarker discovery programmes, however, moving such discov-
eries from bench to clinic remains a costly and time-consuming
process involving many branches of science and medicine.121
Encouraging open communication and collaboration between aca-
demia (basic and clinical research), industry, patients and regula-
tors is, therefore, vital. It is also imperative that pharmaceutical
companies embrace personalised medicine in their clinical
development programmes, perhaps by implementing dedicated
biomarker discovery programmes. With this in mind, the National
Institute of Health Voluntary Genomic Data Submission Program
aims to encourage companies to integrate genomics into their
development programmes by permitting the discussion of genetic
information with the Food and Drug Administration (FDA) in a
forum separate from the product review process.121 Such discussions
may facilitate optimisation of trial designs, thereby helping to
ensure biomarker studies are pre-speciﬁed in large clinical trials
(most current data derive from retrospective analyses or small case
series)122,123 and that new targeted combination strategies are
evaluated effectively. A phase III trial schema that has been proposed
for use in evaluating potential new predictive markers is shown in
Fig. 4.123
Although prospective biomarker studies will undoubtedly
become more commonplace, tissue banks and blood samples from
completed trials will continue to provide a valuable opportunity to
retrospectively link tumour characteristics/blood-borne markers to
clinical outcomes. Genetic epidemiology studies such as GWAS,124
are also important in identifying potential new drug targets. As
such studies yield results, it is important to ensure that all relevant
genomic, transcriptomic and proteomic data are deposited into
freely accessible databases, so that data can be accessed and
processed globally.125
Fig. 4. Trial schema to evaluate a potential new predictive biomarker. Patients with metastatic colorectal cancer (mCRC) would be randomised (in a 2 to 1 ratio) to
stratiﬁcation by the biomarker or to receive unselected/population-based treatment. All three groups of patients would receive the same treatment, giving the potential to
test three hypotheses and link the clinical outcome data to health and economic parameters (that treatment A equals treatment B equals standard therapy). On the basis of
this several hypotheses can be tested. The ﬁrst is that the biomarker-positive group has a superior clinical outcome compared with the biomarker-negative group following
identical treatment. The second hypothesis is that the conventional population-based group has a superior clinical outcome compared with the biomarker-negative group
following identical treatment. The third hypothesis is that the biomarker-positive group has a superior clinical outcome compared with the conventional population-based
group following identical treatment. If sufﬁcient evidence has been accumulated for a particular predictive marker, treatments A and B can differ to test the hypothesis that
distinct treatments result in the same outcomes depending on marker status.123 Reprinted by permission fromMacmillan Publishers Ltd: Walter E, et al. Nat Rev Cancer 2009;
9(7):489–499.
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598 V. Heinemann et al. / Cancer Treatment Reviews 39 (2013) 592–601After its initial identiﬁcation, developing any new biomarker for
clinical use is a time-consuming, multi-step process involving
extensive testing, optimisation and validation. There is also a need
to demonstrate that the new marker offers beneﬁts over currently
available methods i.e. that it has clinical utility. For any new
biomarker, testing should be standardised and diagnostic tests
should be validated with external quality assurance protocols. In
some cases it may be deemed necessary for testing to be performed
in specialised central laboratories to ensure quality. The National
Comprehensive Cancer Network (NCCN) has published a timely
report discussing the importance of the validation and clinical
utility of tumour markers in oncology.126 This report highlights
the importance of both analytic validation (determining how
accurately/reliably a test measures the characteristic of interest)
and clinical validation (assessing the strength of association
between assay result and outcome of interest in biomarker
studies). Importantly, analytic validation also aims to standardise
preanalytic specimen handling, preparation and storage. This
report culminates in a series of recommendations that provide
useful guidance for anyone involved in the tumour biomarker
development process. While the NCCN report focusses on optimising
the conduct of biomarker studies, guidance is now also available in
the form of the REMARK guidelines127,128 as to how biomarker data
should be reported in the literature, but at the moment these focus
only on the reporting studies of potential prognostic markers.
Interestingly, a recent article by one of the authors of the REMARK
guidelines highlighted that the literature on biomarkers continues
to be plagued by issues of non-publication bias, selective reporting
and incomplete reporting and suggested that the development of a
tumour marker registry may help address some of these issues.129
Once a validated diagnostic test is available, it needs to be
brought into clinical use as quickly as possible. For this reason,
co-development programmes are becoming more commonplace,
where diagnostic tests are developed alongside new targeted
therapies. Such programmes have led to the development of
trastuzumab and the Herceptest(Genentech, San Francisco, USA)
for HER-2-positive breast and gastric cancers and, more recently,
vemurafenib (Genentech, San Francisco, USA) and the Cobas
4800 BRAF V600 mutation test (Roche, Pleasanton, USA) for BRAF
V600E-positive melanoma. Once validated, these ‘companion’
diagnostics can be licensed alongside the targeted agent, meaning
that the treatment can be rapidly implemented into clinical
practice as there is already a method available to identify thepatients most likely to beneﬁt. In line with this, in 2011 the FDA
issued draft guidance clarifying that, in instances where the
companion diagnostic is essential for the safe and effective use of
a therapy, both products should be approved together.130 A recent
example of this is for crizotinib (Pﬁzer, New York, USA), a multi-
targeted tyrosine kinase inhibitor, which was approved by the
FDA for the treatment of anaplastic lymphoma kinase (ALK)
rearranged non-small cell lung cancer (NSCLC) alongside its
companion diagnostic – the Vysis ALK Break Apart FISH Probe
Kit (Abbott, Illinois, USA).131 Notably, crizotinib was approved
under the agencies accelerated approval program; no OS data were
submitted and approval was based on ORRs achieved in two
single-arm trials.132 It is also an example of how co-development
programmes can accelerate movement of discoveries from bench
to bedside – it took an unprecedented 4 years from discovery of
the ALK rearrangement in NSCLC to the approval of crizotinib.132
The cost of incorporating any new test into clinical practice is an
important consideration. However, as was seen with KRAS67–71 and
also BRAF99 testing, these costs are likely to be offset by savings in
patient care, such as the cost-saving of avoiding unnecessary
treatment and hospital stays in patients unlikely to respond.Conclusions
Before the era of personalised medicine, cancer diagnosis,
prognosis and treatment decisions were mainly based upon the
histopathologic characteristics of the tumour. Nowadays, a more
holistic approach is being taken where new molecular biomarkers
and bioinformatic patient data are integrated to improve the
accuracy of predicting prognosis and treatment efﬁcacy. Huge
advances have already been made, which can be exempliﬁed by
recent progress in the management of mCRC, particularly the
discovery and implementation of KRAS as a predictive biomarker.
Indeed, the implementation of new technologies is leading to the
accumulation of huge amounts of genomic and proteomic data
and the identiﬁcation and validation of predictive biomarkers for
existing and new targeted therapies, and will likely improve
patient outcomes in the future. Taking discoveries from bench to
clinic is a costly and time-consuming process. Ensuring all
stakeholders across the healthcare spectrum are fully engaged
and understand the importance of personalised medicine will help
ensure that progress in science becomes progress in practice.
V. Heinemann et al. / Cancer Treatment Reviews 39 (2013) 592–601 599Although initial investment may be high, it should ultimately lead
to huge long-term beneﬁts and a cost-effective and rewarding
future for cancer management. Ultimately, the ﬁrst step will
always be to incorporate biomarker discovery and validation into
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